Display options
Cite
Calmeiro J, Carrascal MA, Tavares AR, et al. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics. 2020;12(2)doi: 10.3390/pharmaceutics12020158.
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C., Falcão, A., Cruz, M. T., & Neves, B. M. (2020). Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics, 12(2), . https://doi.org/10.3390/pharmaceutics12020158
Calmeiro, João, et al. "Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells." Pharmaceutics vol. 12,2 (2020). doi: https://doi.org/10.3390/pharmaceutics12020158
Calmeiro J, Carrascal MA, Tavares AR, Ferreira DA, Gomes C, Falcão A, Cruz MT, Neves BM. Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells. Pharmaceutics. 2020 Feb 15;12(2). doi: 10.3390/pharmaceutics12020158. PMID: 32075343; PMCID: PMC7076373.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2020 Feb 15;12(2). doi: 10.3390/pharmaceutics12020158.

Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells.

Pharmaceutics

João Calmeiro, Mylène A Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Célia Gomes, Amílcar Falcão, Maria Teresa Cruz, Bruno Miguel Neves

Affiliations

  1. Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.
  2. Center for Neuroscience and Cell Biology-CNC, University of Coimbra, 3004-504 Coimbra, Portugal.
  3. Tecnimede Group, 2710-089 Sintra, Portugal.
  4. Coimbra Institute for Clinical and Biomedical Research-iCBR, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
  5. Center for Innovation in Biomedicine and Biotechnology-CIBB, University of Coimbra, 3004-504 Coimbra, Portugal.
  6. Coimbra Institute for Biomedical Imaging and Translational Research-CIBIT, University of Coimbra, 3000-548 Coimbra, Portugal.
  7. Department of Medical Sciences and Institute of Biomedicine-iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal.

PMID: 32075343 PMCID: PMC7076373 DOI: 10.3390/pharmaceutics12020158

Abstract

Throughout the last decades, dendritic cell (DC)-based anti-tumor vaccines have proven to be a safe therapeutic approach, although with inconsistent clinical results. The functional limitations of ex vivo monocyte-derived dendritic cells (MoDCs) commonly used in these therapies are one of the pointed explanations for their lack of robustness. Therefore, a great effort has been made to identify DC subsets with superior features for the establishment of effective anti-tumor responses and to apply them in therapeutic approaches. Among characterized human DC subpopulations, conventional type 1 DCs (cDC1) have emerged as a highly desirable tool for empowering anti-tumor immunity. This DC subset excels in its capacity to prime antigen-specific cytotoxic T cells and to activate natural killer (NK) and natural killer T (NKT) cells, which are critical factors for an effective anti-tumor immune response. Here, we sought to revise the immunobiology of cDC1 from their ontogeny to their development, regulation and heterogeneity. We also address the role of this functionally thrilling DC subset in anti-tumor immune responses and the most recent efforts to apply it in cancer immunotherapy.

Keywords: CD141+XCR1+ DCs; anti-tumor immunotherapy; conventional type 1 dendritic cells; dendritic cell-based vaccines

References

  1. J Exp Med. 2013 May 6;210(5):1035-47 - PubMed
  2. Cancer Cell. 2017 May 8;31(5):711-723.e4 - PubMed
  3. Clin Cancer Res. 2016 May 1;22(9):2155-66 - PubMed
  4. Blood. 2013 Jan 17;121(3):459-67 - PubMed
  5. Immunity. 2011 Aug 26;35(2):161-8 - PubMed
  6. Science. 2015 May 15;348(6236):803-8 - PubMed
  7. Cancer Cell. 2015 Apr 13;27(4):450-61 - PubMed
  8. J Immunol. 2004 Aug 15;173(4):2780-91 - PubMed
  9. Nat Commun. 2016 Dec 23;7:13720 - PubMed
  10. Methods Mol Biol. 2016;1423:19-37 - PubMed
  11. J Clin Invest. 2008 Jun;118(6):2098-110 - PubMed
  12. Eur J Immunol. 2014 Jul;44(7):1947-55 - PubMed
  13. Int J Cancer. 2015 Mar 1;136(5):1085-94 - PubMed
  14. N Engl J Med. 1977 Sep 1;297(9):484-91 - PubMed
  15. Nat Med. 2018 Aug;24(8):1178-1191 - PubMed
  16. Nat Rev Drug Discov. 2015 Jul;14(7):487-98 - PubMed
  17. Stem Cells Dev. 2014 May 1;23(9):955-67 - PubMed
  18. J Exp Med. 2016 Jan 11;213(1):75-92 - PubMed
  19. Nat Rev Immunol. 2012 Jul 13;12(8):557-69 - PubMed
  20. Cancer Immunol Immunother. 2019 Oct;68(10):1605-1619 - PubMed
  21. Annu Rev Immunol. 2013;31:563-604 - PubMed
  22. Transl Lung Cancer Res. 2017 Apr;6(2):220-229 - PubMed
  23. Immunity. 2009 Nov 20;31(5):823-33 - PubMed
  24. Cancer Res. 2008 Oct 15;68(20):8437-45 - PubMed
  25. J Immunother. 2007 Feb-Mar;30(2):227-33 - PubMed
  26. Front Immunol. 2017 Jun 28;8:760 - PubMed
  27. Front Immunol. 2018 Dec 13;9:2806 - PubMed
  28. Front Immunol. 2012 Feb 07;3:13 - PubMed
  29. Cancer Res. 2013 Feb 1;73(3):1063-75 - PubMed
  30. Cancer Treat Rev. 2017 Mar;54:74-86 - PubMed
  31. Cancer Cell. 2016 Aug 8;30(2):324-336 - PubMed
  32. Oncotarget. 2016 Jun 28;7(26):40437-40450 - PubMed
  33. Nat Rev Cancer. 2018 May;18(5):313-322 - PubMed
  34. J Immunol. 2015 Jun 15;194(12):5895-902 - PubMed
  35. Front Immunol. 2015 Jan 28;6:13 - PubMed
  36. Clin Cancer Res. 2009 Apr 1;15(7):2531-40 - PubMed
  37. Gene Ther. 2012 Oct;19(10):1035-40 - PubMed
  38. Cell Res. 2017 Jan;27(1):74-95 - PubMed
  39. Cancer Immunol Res. 2017 Dec;5(12):1098-1108 - PubMed
  40. J Exp Med. 2010 Jun 7;207(6):1273-81 - PubMed
  41. Lancet Oncol. 2014 Jun;15(7):e257-67 - PubMed
  42. J Exp Med. 2010 Jun 7;207(6):1261-71 - PubMed
  43. Front Immunol. 2014 Apr 11;5:165 - PubMed
  44. J Exp Med. 2015 Mar 9;212(3):401-13 - PubMed
  45. Immunity. 2017 Feb 21;46(2):205-219 - PubMed
  46. Front Immunol. 2019 May 29;10:1195 - PubMed
  47. J Immunother. 2015 Feb-Mar;38(2):71-6 - PubMed
  48. Front Immunol. 2019 Feb 12;10:9 - PubMed
  49. Nat Rev Drug Discov. 2014 May;13(5):379-95 - PubMed
  50. Future Oncol. 2012 Oct;8(10):1273-99 - PubMed
  51. Hum Vaccin Immunother. 2016 Mar 3;12(3):607-11 - PubMed
  52. Sci Immunol. 2018 Dec 7;3(30): - PubMed
  53. Methods Mol Biol. 2016;1423:61-87 - PubMed
  54. J Exp Med. 2010 Jun 7;207(6):1247-60 - PubMed
  55. J Immunol. 2004 Jan 1;172(1):123-9 - PubMed
  56. Cancer Res. 2013 Aug 1;73(15):4653-62 - PubMed
  57. Cell Rep. 2019 Oct 1;29(1):162-175.e9 - PubMed
  58. Cancer Sci. 2015 Aug;106(8):945-50 - PubMed
  59. Trends Immunol. 2012 Aug;33(8):381-8 - PubMed
  60. Eur J Immunol. 2010 May;40(5):1255-65 - PubMed
  61. Curr Opin Immunol. 2015 Feb;32:13-20 - PubMed
  62. BMC Med. 2016 May 05;14:73 - PubMed
  63. Immunity. 2013 Jul 25;39(1):38-48 - PubMed
  64. J Clin Invest. 2018 May 1;128(5):1971-1984 - PubMed
  65. J Immunol. 2013 Jun 15;190(12):6071-82 - PubMed
  66. Oncoimmunology. 2013 Mar 1;2(3):e23140 - PubMed
  67. Science. 2008 Nov 14;322(5904):1097-100 - PubMed
  68. Nat Immunol. 2018 Aug;19(8):885-897 - PubMed
  69. Cancer Cell. 2014 Nov 10;26(5):638-52 - PubMed
  70. Eur J Immunol. 2014 Jun;44(6):1582-92 - PubMed
  71. Front Immunol. 2012 Feb 10;3:14 - PubMed
  72. Front Immunol. 2019 May 31;10:1205 - PubMed
  73. J Exp Med. 2010 Jun 7;207(6):1283-92 - PubMed
  74. Cancer Res. 1995 Aug 15;55(16):3486-9 - PubMed
  75. Sci Rep. 2016 Mar 23;6:23505 - PubMed
  76. J Immunol. 2015 Feb 1;194(3):1069-79 - PubMed
  77. Crit Rev Oncog. 2014;19(1-2):91-105 - PubMed
  78. Front Immunol. 2014 Apr 15;5:174 - PubMed
  79. Nature. 2009 Apr 16;458(7240):899-903 - PubMed
  80. J Immunother Cancer. 2019 Nov 14;7(1):302 - PubMed
  81. Trends Cancer. 2018 Nov;4(11):784-792 - PubMed
  82. Adv Immunol. 2013;120:1-49 - PubMed
  83. Nat Immunol. 2012 Sep;13(9):888-99 - PubMed
  84. Science. 2003 Apr 11;300(5617):339-42 - PubMed
  85. Front Immunol. 2012 Jul 18;3:214 - PubMed
  86. Blood. 2008 Oct 15;112(8):3264-73 - PubMed
  87. Nat Biomed Eng. 2018 Jun;2(6):341-346 - PubMed
  88. Clin Cancer Res. 2015 Nov 15;21(22):5047-56 - PubMed
  89. Oncoimmunology. 2016 May 05;5(6):e1168555 - PubMed
  90. Immunity. 2012 Jul 27;37(1):60-73 - PubMed
  91. Nat Commun. 2015 Jun 25;6:7458 - PubMed
  92. Br J Cancer. 2013 Apr 30;108(8):1560-5 - PubMed
  93. Clin Cancer Res. 2011 Apr 1;17(7):1984-97 - PubMed
  94. Cancer Immunol Res. 2015 May;3(5):495-505 - PubMed
  95. J Immunother Cancer. 2019 Apr 8;7(1):100 - PubMed
  96. J Immunol. 2014 Aug 15;193(4):1622-35 - PubMed
  97. Cell Rep. 2018 Aug 14;24(7):1902-1915.e6 - PubMed
  98. Front Immunol. 2014 Apr 10;5:159 - PubMed
  99. Blood. 2005 Oct 1;106(7):2252-8 - PubMed
  100. Nat Med. 2008 Jun;14(6):623-8 - PubMed
  101. Cytotherapy. 2019 Oct;21(10):1049-1063 - PubMed
  102. Immunity. 2012 Apr 20;36(4):646-57 - PubMed
  103. Cancer Cell. 2014 Nov 10;26(5):623-37 - PubMed
  104. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  105. Transl Res. 2016 Feb;168:74-95 - PubMed
  106. World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):133-8 - PubMed
  107. Immunity. 2016 Apr 19;44(4):924-38 - PubMed
  108. J Immunother Cancer. 2019 Apr 18;7(1):109 - PubMed
  109. Oncoimmunology. 2015 Apr 2;4(8):e1019198 - PubMed
  110. Allergol Int. 2007 Sep;56(3):215-23 - PubMed
  111. J Immunother Cancer. 2019 Sep 4;7(1):238 - PubMed
  112. Nature. 2007 Sep 27;449(7161):419-26 - PubMed
  113. Cancer Discov. 2016 Jan;6(1):71-9 - PubMed
  114. Blood. 2003 Mar 1;101(5):1718-26 - PubMed
  115. Semin Cancer Biol. 1991 Oct;2(5):347-54 - PubMed
  116. Immunology. 2018 May;154(1):3-20 - PubMed
  117. Gan To Kagaku Ryoho. 2018 Oct;45(10):1469-1471 - PubMed
  118. Hum Mol Genet. 2015 Oct 15;24(R1):R67-73 - PubMed
  119. Nature. 2015 Jul 9;523(7559):231-5 - PubMed
  120. Annu Rev Immunol. 2012;30:1-22 - PubMed
  121. Front Immunol. 2018 Jul 02;9:1499 - PubMed
  122. Cell. 2019 Oct 31;179(4):846-863.e24 - PubMed
  123. J Immunol. 2005 Mar 1;174(5):2591-601 - PubMed
  124. Cell. 2018 Feb 22;172(5):1022-1037.e14 - PubMed

Publication Types

Grant support